Laddar populära aktier...
Redeye sees a Q2 report roughly matching our expectations.
Small Q2 beat amid solid underlying performance In strong position to act on opportunities Fair valu...
Luxbright AB (”Luxbright” eller ”Bolaget”) har publicerat Bolagets delårsrapport för det första halv...
Redeye provides its comment on Mendus’ Q2 2024 report.
I en utmanande omgivning tar New Wave marknadsandelar och ökar nu marknadssatsningarna.
Redeye regards BrightBid’s Q2 as a mixed-bag quarter, where the substantial cost cuts are the positi...
CoinShares International (CS) posted a strong adjusted EBITDA in Q224 of £26.
Solteq is set to start showing clearly improved profitability figures, with the toughest actions now...
Redeye returns with an updated view of Egetis Therapeutics following the Q2 report and recent events...
Redeye comments on Heliospectra’s Q2 results, noting that sales were weaker than expected due to sho...
Redeye provides an initial comment on the Q2 2024 report from Kancera, which showed lower operating ...
CirChem (”CirChem” eller ”Bolaget”) har nyligen stängt böckerna för Q2-24, ett kvartal präglat av fo...
Redeye provides a research update following the Q2 report recently published by Coegin Pharma.
Redeye’s long-term view of Dignitana is, to a degree, intact, even if the sales progression has been...
Gapwaves carried over its momentum from Q1 into the Q2 report, beating Redeye's estimates and consen...
